Halozyme Therapeutics HALO Corporate Presentation May 2023

Halozyme Therapeutics licenses its ENHANZE drug delivery platform to partners and commercializes specialty products for subcutaneous delivery. The company's technology has enabled five globally-approved partnered products across 100+ countries, with approximately 700,000 patients having received ENHANZE-enabled treatments. Halozyme also develops auto-injectors and specialty devices for broad therapeutic applications.